Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company released its 3Q2024 financial results that showed good cash, low debt and good cost controls.</li><li>Recently, the company also announced the first human patients have been treated with NB1, marking an important milestone for BBLG.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company released its 3Q2024 financial results that showed good cash, low debt and good cost controls.Recently, the company also announced the first human patients have been treated with NB1, marking an important milestone for BBLG.

BBLG: Cash in Good Shape as Trials Continue

<ul><li>Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.</li><li> The company released its 2Q2024 financial results that showed good cash, low debt and good cost controls.</li><li>Recently, the company also announced the first human patients have been treated with NB1, marking an important milestone for BBLG.</li></ul>

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company released its 2Q2024 financial results that showed good cash, low debt and good cost controls.Recently, the company also announced the first human patients have been treated with NB1, marking an important milestone for BBLG.

BBLG: Improved Balance Sheet as Trials Continue

United States

Bone Biologics Corporation operates as a biotechnology company. The Company focuses on bone regeneration in human lumbar spinal fusion using recombinant human protein growth factor. Bone Biologics offers bone repair and regeneration applications in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bone Biologics (BBLG US)

BBLG: Cash in Good Shape as Trials Continue

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

BBLG: Improved Balance Sheet as Trials Continue

Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)